Neurosense Therapeutics Files for Resale of Up to 5.28 Million Shares

MT Newswires2024/12/27 06:30

NeuroSense Signs Term Sheet for Phase 3 PrimeC Trial in Amyotrophic Lateral Sclerosis

MT Newswires2024/12/23 22:44

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

PR Newswire2024/12/23 22:00

NeuroSense Therapeutics Shares Are Trading Higher. The Stock May Be Moving on a Continued Strength After the Company Reported on Wednesday a Year-over-year Increase in 9-month EPS Results.

Benzinga2024/12/20 04:29

NeuroSense Therapeutics: Expect to Submit a Dossier in 2Q 2025, With a Regulatory Decision Expected by 1Q 2026 >NRSN

Dow Jones2024/12/18 23:30

NeuroSense Therapeutics: Estimate Potential Market Opportunity in Canada Is Between $100M to $150M in Peak Annual Rev >NRSN

Dow Jones2024/12/18 23:30